Clinical Trials Logo

Clinical Trial Summary

The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for seizure.


Clinical Trial Description

This was a multicenter, single-arm, open-label, postmarketing safety study to evaluate the risk of seizure among patients with mCRPC treated with enzalutamide who were at potential increased risk of seizure. Participants who met all inclusion and none of the exclusion criteria were enrolled into the study and participated in a 4-month treatment period, during which once daily dosing of enzalutamide (160 mg/day) occurred. At the end of the 4-month treatment period, participants who were assessed as deriving benefit from enzalutamide treatment were allowed to continue in the extension period where participants continued to receive enzalutamide until 1 of the following criteria was met: 1. The participant experienced bone disease progression per Prostate Cancer Working Group 2 (PCWG2) guidelines or soft tissue disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 2. The participant initiated treatment with another anticancer therapy or, in the opinion of the investigator, continued dosing would have led to undue risk to the patient 3. The participant met a discontinuation criterion 4. The sponsor terminated the study Participants who continued to receive clinical benefit from treatment with enzalutamide and did not meet any discontinuation criteria may have transitioned to an open label roll-over extension study upon approval of the study protocol at the institution where they were receiving treatment. Participants who did not continue in the extension period or who met a discontinuation criterion were discontinued from enzalutamide therapy and completed a follow-up visit 30 days from the last dose of enzalutamide or prior to the initiation of another anticancer therapy, whichever occurred first. For participants who continued on treatment after the 12-month extension period, data collection was limited to dosing information, concomitant medications, and all adverse events (AEs) including serious adverse events (SAEs). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01977651
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Completed
Phase Phase 4
Start date September 25, 2013
Completion date January 11, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT04015622 - PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA Phase 2
Recruiting NCT06344715 - Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. Phase 1
Recruiting NCT05983198 - A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy. Phase 1/Phase 2
Not yet recruiting NCT06134232 - Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T Phase 3
Recruiting NCT06126731 - Combination Study of Antibiotics With Enzalutamide (PROMIZE) Phase 1/Phase 2
Recruiting NCT05806814 - Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer Phase 1
Active, not recruiting NCT05658003 - A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer Phase 2
Active, not recruiting NCT05670106 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC Phase 2
Recruiting NCT04691804 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 3
Completed NCT03896984 - Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
Recruiting NCT06334432 - Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03074032 - Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer Phase 1
Recruiting NCT05032040 - A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Phase 2
Completed NCT03071328 - INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers Early Phase 1
Active, not recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Completed NCT03030885 - Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1
Terminated NCT03712930 - Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Phase 2
Recruiting NCT06241846 - A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC Phase 2
Recruiting NCT03903835 - ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer Phase 3